Please login to the form below

Not currently logged in
Email:
Password:

Lupin appoints European president

Maurice Chagnaud moves to India-based company from Teva

India-based Lupin has appointed former Teva senior VP Dr Maurice Chagnaud as president of its European business and head of inhalation strategy.

Dr Chagnaud will be based at the company's operations in Schaffhausen, Switzerland, where he will be responsible for Lupin's business strategy in Europe, including Russia and the CIS countries.

He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets.

Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva. He was with Teva for just under seven years, with other roles include chief commercial officer in Europe and CEO of the company's operations in France.

In addition, Dr Chagnaud's industry experience also includes time as general manager for Merck KGaA'a generics business in Italy.

20th February 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics